THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 52 filers reported holding THESEUS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,169 | -70.1% | 10,100 | +3.7% | 0.00% | -100.0% |
| Q2 2023 | $90,884 | +24.8% | 9,741 | +18.8% | 0.00% | – |
| Q1 2023 | $72,825 | +82.0% | 8,201 | +2.0% | 0.00% | – |
| Q4 2022 | $40,024 | -14.8% | 8,037 | -0.4% | 0.00% | – |
| Q3 2022 | $47,000 | +6.8% | 8,066 | +1.4% | 0.00% | – |
| Q2 2022 | $44,000 | -33.3% | 7,952 | +39.2% | 0.00% | – |
| Q1 2022 | $66,000 | -15.4% | 5,714 | -6.6% | 0.00% | – |
| Q4 2021 | $78,000 | – | 6,116 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,585,346 | $31,837,872 | 23.54% |
| Lynx1 Capital Management LP | 761,258 | $6,759,971 | 5.64% |
| Omega Fund Management, LLC | 711,479 | $6,317,934 | 4.12% |
| Orbimed Advisors | 17,233,668 | $153,034,972 | 3.00% |
| Fairmount Funds Management LLC | 1,865,671 | $16,567,158 | 2.85% |
| Nextech Invest Ltd. | 611,310 | $5,428,433 | 2.27% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $19,963,963 | 1.44% |
| VR Adviser, LLC | 770,000 | $6,837,600 | 1.34% |
| Opaleye Management Inc. | 488,100 | $4,334,328 | 1.30% |
| Paradigm Biocapital Advisors LP | 1,505,327 | $13,367,304 | 1.27% |